Kewei Ma

15PUBLICATIONS
9CO-AUTHORS
Molecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)ChemotherapyCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Feb 29, 2024
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study.

Jing Zheng, Tao Wang, Yunpeng Yang

|Dec 19, 2023
Imaging findings can't mean everything in the era of immunotherapy: a case report and literature review.

Xiangye Zhao, Kewei Ma, Xiaobo Ma

|Sep 22, 2022
Efficacy of Immunotherapy Combined with Antiangiogenic Therapy in Treatment-Failure Patients with Advanced Carcinoma Ex Pleomorphic Adenoma of the Submandibular Gland: A Case Report.

Huanlan Sa, Yinghui Xu, Xiaobo Ma

|Sep 09, 2022
A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second-line treatment in advanced small cell lung cancer.

Yinghui Xu, Xu Wang, Chao Sun

|Feb 22, 2022
Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.

Chao Sun, Yunpeng Liu, Peng Zhang

|Dec 28, 2021
Combined targeting of EGFR and BRAF triggers regression of osimertinib resistance by using osimertinib and vemurafenib concurrently in a patient with heterogeneity between different lesions.

Mengyao Sun, Xu Wang, Yinghui Xu

Pageof 3

Frequent Collaborators

1 joint publications

Junya Song

1 joint publications

Zihua Zou

1 joint publications

Yangchun Gu

1 joint publications

Puyuan Xing